CTEV
ClaritevBNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
Q1 showed continued revenue growth and solid adjusted EBITDA, while PHCS Novera gives Claritev a tangible 2026 product-rollout path. If management can keep growth moving and convert the launch into commercial wins while holding covenant compliance and improving cash flow, the equity can rerate from a depressed leverage discount.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Gross debt remains high at roughly $4.6 billion, so interest burden and refinancing sensitivity still matter.
Momentum
77
Value
52
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.50 · Bull $31.00 · Bear $9.50
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $37.67
Why
Momentum77 · Δ7d -0.4
Value52 · Δ7d +0.2
Sentiment42 · Δ7d -1.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
77
26% active weight
Current posture
7d trendImproving
Δ7d
-0.4
Δ21d
-8.8
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.6
Sentiment
42
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
+8.7
Why this grade
Composite grade B. Momentum 77.2 / Value 52.4 / Sentiment 41.8
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$489.1M
Beta
0.53
Shares Out
17.05M
P/E (TTM) · Derived
-1.7
P/S (TTM)
0.51
P/FCF (TTM) · Derived
-15.50
Rev YoY
+5.8%
EPS YoY
+0.6%
Gross Margin
+27.7%
Op Margin
-8.1%
Net Debt
$4.59B
Current Ratio
1.28
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology